Literature DB >> 17671705

Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.

Isamu Hoshino1, Hisahiro Matsubara, Yasunori Akutsu, Takanori Nishimori, Yasuo Yoneyama, Kentaro Murakami, Aki Komatsu, Haruhito Sakata, Kazuyuki Matsushita, Takenori Ochiai.   

Abstract

Histone deacetylase inhibitors (HDACIs) are promising therapeutic agents with the potential for regulating cell cycle, differentiation and apoptosis in cancer cells. HDACI activity is associated with selective transcriptional regulation and altering gene expression. However, the exact mechanisms leading to the antitumor effect of HDACIs are not fully understood. FK228, one of the powerful HDACIs, strongly inhibited cell growth of T.Tn and TE2 cells and induced apoptosis. Therefore, comprehensive analysis of the changes in gene expression in human esophageal cancer cell lines by the HDACI FK228 was carried out by microarray analysis. This analysis was used to clarify the expression profiles of genes after exposure to FK228. Of the 4,608 genes analyzed, 93 genes in T.Tn and 65 genes in TE2 were up- or down-regulated 2-fold or more at least at one time point during FK228 exposure and they were classified into four clusters based on their expression patterns. Among them, 15 genes were contained in both cell lines and their expression patterns were similar. Except p21, Prdx1 (reported by us) and IGFBP3, the behaviour/expression of 12 highly responsive genes has still not been reported in esophageal cancer cells. These observations of the expression patterns of functionally classified genes provided insights into the mechanism of the antitumor effect of FK228 in esophageal squamous carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671705

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

Review 1.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

2.  The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.

Authors:  Angelika Danielsson; Helena Dzojic; Victoria Rashkova; Wing-Shing Cheng; Magnus Essand
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

3.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Authors:  Manoj Kumar Kashyap; H C Harsha; Santosh Renuse; Harsh Pawar; Nandini A Sahasrabuddhe; Min-Sik Kim; Arivusudar Marimuthu; Shivakumar Keerthikumar; Babylakshmi Muthusamy; Kumaran Kandasamy; Yashwanth Subbannayya; Thottethodi Subrahmanya Keshava Prasad; Riaz Mahmood; Raghothama Chaerkady; Stephen J Meltzer; Rekha V Kumar; Anil K Rustgi; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

4.  Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.

Authors:  Theresa D Ahrens; Sylvia Timme; Jens Hoeppner; Jenny Ostendorp; Sina Hembach; Marie Follo; Ulrich T Hopt; Martin Werner; Hauke Busch; Melanie Boerries; Silke Lassmann
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 5.  Recent advances in histone deacetylase targeted cancer therapy.

Authors:  Isamu Hoshino; Hisahiro Matsubara
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.